Cel Sci (CVM) Cash from Investing Activities (QoQ) (2010 - 2024)
Cel Sci (CVM) Cash from Investing Activities (QoQ) (2010 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -66.83% |
| Sep 30, 2024 | 15.84% |
| Dec 31, 2023 | -525.47% |
| Sep 30, 2023 | 94.73% |
| Jun 30, 2023 | -76.63% |
| Mar 31, 2023 | -108.01% |
| Dec 31, 2022 | -233.50% |
| Sep 30, 2022 | 77.36% |
| Jun 30, 2022 | 86.71% |
| Mar 31, 2022 | -108.73% |
| Dec 31, 2021 | 33.18% |
| Sep 30, 2021 | 329.53% |
| Jun 30, 2021 | 86.33% |
| Mar 31, 2021 | -364.31% |
| Dec 31, 2020 | -180.09% |
| Sep 30, 2020 | -39.96% |
| Jun 30, 2020 | -22.28% |
| Mar 31, 2020 | -498.93% |
| Dec 31, 2019 | -123.71% |
| Sep 30, 2019 | 15.76% |